Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karrar Mohammed Hasan Al-Gburi has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    DESIGN AND COMPUTATIONAL ANALYSIS OF NEW ISATIN-IMINE HYBRIDS AS SELECTIVE HDAC6 INHIBITORS

    by Karrar Al-Gburi, Noor H. Naser, Malina Jasmi

    Objective: Emerging evidence highlights the critical role of Histone Deacetylase (HDAC) 6 in various pathologies, including cancer and neurodegenerative diseases. Therefore, we sought to computationally study new isatin-imine hybrid compounds to predict their Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiles and binding mode with HDAC6 through docking and molecular dynamics simulations. Methods: ADMET and drug-likeness properties of target compounds were predicted using ADMETlab 3.0. Molecular docking was conducted using Autodock4Zn embedded in Amdock v1.5.2 against HDAC6, HDAC8, and HDAC2. Utilizing Newton's equations of motion in conjunction with the Desmond package from the Schrödinger software suite, a molecular dynamics simulation of 100 nanoseconds was conducted to investigate protein-ligand interactions at the atomic level. Results: All compounds exhibited favorable physicochemical characteristics and met drug-likeness criteria, showing good absorption profile, high protein binding (except Km73 and Km74), and Human Liver Microsomal enzyme stability. Three compounds (Km66, Km68, and Km74) had low plasma clearance, while Km69, Km72, and Km73 had moderate clearance. Compounds were predicted to have favorable toxicity profiles. In docking studies on HDAC6, all compounds showed higher binding affinities (-7.44 to-10.69 Kcal/mol) than the reference compounds SAHA and Nexturastat A. For HDAC2, all compounds had a lower binding affinity than for HDAC6, except Km68, which showed a higher affinity for HDAC2 (-10.61 vs.-9.23 Kcal/mol). Km68 and Km69 demonstrated stable binding modes in molecular dynamics simulations, while Km68 showed some deviations. Conclusion: Our findings indicate that all compounds demonstrate favorable ADMET profiles, binding affinities, and selectivity towards HDAC6. Their predicted binding affinity has outperformed that of reference compounds, including SAHA and HDAC6-selective nexturastat A. This suggests that these compounds have the potential to be promising candidates for selective inhibition of HDAC6, thereby opening up new possibilities in drug development.


  • Open Access

    PREPARATION AND OPTIMIZATION OF CILOSTAZOL NANOEMULSION ORAL LIQUID DOSAGE FORM

    by Abulfadhel Jaber Neamah Al-Shaibani, Karrar Al-Gburi, Karrar Talib Khudhair Albo Hamrah

    Objective: Cilostazol has poor water solubility and low oral bioavailability. Therefore, the formulation of cilostazol as a nanoemulsion may enhance its solubility and improve oral bioavailability. Hence, the aim of this study was to formulate and characterize an oil-in-water (o/w) nanoemulsion of cilostazol as an oral liquid dosage form. Methods: Pseudo-ternary phase diagrams were constructed using the aqueous titration method. Formulations of pseudo-ternary phase plots consisting of oil, various weight ratios of S mix (mixture of surfactant and co-surfactant), and deionized water were made. Different characterization studies, droplet size measurement, polydispersity index, drug content, zeta potential measurement, and in vitro release have been conducted to choose the optimized formula. Results: The characterization studies have demonstrated that the optimized formula is (F-6), consisting of 20 % S mix (3:1), 10% ginger oil, and 70% deionized water. This formula had the following characteristics; droplet size (72.9-110 nm), polydispersity index (0.22), percentage of drug content (99.8%), and in vitro release of cilostazol nanoemulsion was significantly higher (PConclusion: In conclusion, the optimized cilostazol formula (F-6) is a promising formula which may have the capability of improving the oral bioavailability of cilostazol.


  • Tobacco smoking and substance use among medical undergraduates in Najaf, Iraq: prevalence and associated factors

    by Karrar Al-Gburi, Ali Mohammed Abd Alridha, Sarah Kadhim Abbood, Ahmed Basim Ali, Ali Talib Salih

    Tobacco smoking and substance use is a public health hazard. The investigations studying tobacco smoking, substance use, and their associated factors among Iraqi undergraduates are limited. Our stu...


  • Open Access

    A COMPARATIVE STUDY OF QUALITY CONTROL TESTING OF MEFENAMIC ACID TABLETS IN IRAQ

    by Inas F. Abdulrazzaq, Yasmien A. Salal, Mazin Thamir Abdul-Hasan, Hayder K. Abbas, Karrar Mohammed Hasan Al-Gburi

    Objective: This research was performed to assess the quality of different marketed tablets having mefenamic acid (500 mg). The selected tablets are produced by numerous companies and presented in the Iraqi pharmaceutical marketplace. Methods: Different batches of mefenamic acid conventional tablets were exposed for several tests of quality control. These evaluation tests include hardness, weight variation, friability, disintegration time, drug content, and drug dissolution profile. The properties of these quality tests were made conferring to the specification of USP-pharmacopeia. Results: The data of this study indicate that each tablet of mefenamic acid batches conformed to the requirement of USP pharmacopeia, the hardness was (6.87-8.06 Kg/cm2), and the drug content results were (90.666-99.214%) within USP limitation. The data of disintegration time and weight uniformity were agreeable with pharmacopeia and the in vitro release assay showed that the release of each mefenamic acid marketed tablet was highest than (80 %) in 45 min, which reproducing compliance with the USP pharmacopeia's limitation. Conclusion: From this study, it was proved that all of the marketed brands of mefenamic acid tablets meet the standard character in the USP pharmacopeia for in vitro quality control tests.


  • Open Access

    QUALITY EVALUATION OF BRANDS OF PROPRANOLOL HCL TABLETS AVAILABLE ON IRAQI MARKET

    by Mazin Thamir Abdul-Hasan, Krar Kadhim Mohammed Jawad, Abulfadhel Jaber Neamah Al-Shaibani, Karrar Mohammed Hasan Al-Gburi

    Objective: The purpose of this study is to evaluate the quality control of marketed tablets containing propranolol hydrochloride available on the Iraqi market and manufactured by different companies. Methods: Different batches of propranolol hydrochloride 40 mg tablets were assessed using quality control tests. Weight variation, diameter, thickness, friability, disintegration time and dissolution study were carried out in this study. Results: Based on the data obtained in this study, all brands of PPL available on the Iraqi market showed weight variation within the acceptable limit of USP. Marketed products of Becardin and Propranolol lie within the acceptable limit of hardness and Inderal was observed to be slightly higher than the normal upper range of USP. Diameter and thickness for all brands were almost the same, except the diameter of Becardin was slightly higher and friability was zero for all brands. All brands demonstrated a time of disintegration of fewer than 30 min. The tested marketed propranolol products; Inderal, Procard, Becardin and Propranolol showed cumulative drug release of 90.08%, 94.46%, 92.4% and 79.51%, respectively at the end of the first 20 min. This variation in the release profile of marketed tablets of Propranolol HCl might be attributed to the excipients present in the marketed tablets where some of these excipients may behave as a disintegrant and enhance dissolution rate while others may act as dissolution retardants. Conclusion: All marketed tablets of Propranolol HCl employed in this study were produced within the standard criteria of tablet manufacturing. Evaluation of quality control of these selected tablets showed acceptable pharmaceutical properties that lie within the limits of USP.


  • Open Access

    QUALITY CONTROL TESTING OF CONVENTIONAL CLOPIDOGREL BISULFATE TABLETS MARKETED IN IRAQ

    by Mazin Thamir Abdul-Hasan, Abulfadhel Jaber Neamah Al-Shaibani, Ali N. Wannas, Karrar Mohammed Hasan Al-Gburi

    Objective: This study was employed to evaluate the quality of marketed oral tablets containing clopidogrel bisulfate. Tablets produced by various companies and commercialized in the Iraq market were used in the study. Methods: Batches of clopidogrel bisulfate conventional tablets (containing 75 mg of drug) were exposed to the quality control tests. These tests involved friability, weight variation, hardness, drug content, disintegration time, and in vitro release study; these tests were conducted depending on USP pharmacopeia. Results: The data indicate that all batches of clopidogrel bisulfate complied with the limitations of USP pharmacopeia for variation of weight, results of the hardness of tablets were 7.2-9.6 Kg/cm2. Friability value (% loss) was less than one, which was within the required limits. The time of disintegration was less than 25 min in both artificial gastric fluid (AGF) and artificial intestinal fluid (AIF). Drug content was observed between 97.1 % and 99.8 %, indicating compliance with the limits of pharmacopeia (85-115 %). An in vitro release study of batches was greater than 80 % within 25 min. Conclusion: All batches of clopidogrel bisulfate were manufactured within the criteria of tablet manufacturing. The quality control tests of tablets showed acceptable pharmaceutical properties (effectiveness and safety) that lie within the limits of USP pharmacopeia.


  • Pattern and Correlates of Hypomagnesemia Among Subset of Diabetes Mellitus

    by Ihasn Salah Rabea, Karrar Al-Gburi, Ihsan Adnan, Bilal Hasan, Massa Mohammed, Mariam Mohammed

    Background: Nowadays, there is an accumulated data about the relation between hypomagnesemia (low Serum Mg level < 0.7 mmol/l) and diabetes. Objective: In this study, we aimed to determine the prevalence of hypomagnesemia in a carefully diagnosed diabetes patients and to show how some factors could contribute to the prevalence of low serum Mg level among the population under study. Methods: In short, 62 patients of both type 1 and 2, who attended AL-Sadir medical city/ diabetes and endocrinology centre during the period of the study were included in the study. A detailed history was taken and participants were informed verbally about the procedure of this study. Serum magnesium and creatinine were measured using standardized methods. Results: The overall prevalence of the hypomagnesemia, among diabetic population involved in this study, was 29.03 % and it was nearly similar in male (29.41 %) and female (28.57 %). The means(SD) of serum Mg level were similar in type 1 and type 2 diabetic patients. Other difference in prevalence among other characteristics has been reported. Within all participants, gender (r = -0.02), fasting blood glucose (r = -0.514) and metformin use (r = -0.014) were negatively correlated with serum Mg level, in contrast to other variables, which were positively correlated. While among type 1 DM, age (r= 0.193), serum creatinine (r= 0.031) and insulin use (r= 0.217) were positively correlated with serum Mg level. In contrast, others were negatively correlated. In type 2 DM, age (r = -0.283) and fasting blood glucose (r = -0.496) were negatively correlated with serum Mg level. On the other hand, other variables were positively correlated with serum Mg level. Conclusion: Hypomagnesemia prevalence was detected in nearly one-third of the diabetic population, which is quite high prevalence. Some factors have shown to play an essential role in this prevalence. A large study is warranted to address this issue.


  • A cross-sectional study of epidemiological factors associated with drug use among secondary school students

    by Karrar Al-Gburi, Roaa Al-Murshedi, Ali Mohammed Abd Alridha, Hasan Baiee

    Objective: Few data are available about drug use among Iraqi society, especially among people within the most vulnerable period, adolescence and secondary education. Hence, this study was designed to determine the prevalence and to examine the epidemiological factors associated with drug use among secondary school students. Methods: A descriptive cross-sectional school-based study was designed and students were selected using a multistage sampling method during the period from March through April 2018 in Al-Hilla city – Babil – Iraq. In the first stage, 15 secondary schools were selected using cluster sampling. Students at each secondary school, one study hall classroom per grade level were randomly selected to participate in the second stage of this study. Chi-square was used to determine if certain factors are associated significantly (pvalue ≤0.05) with drug use. Results: The overall prevalence of drug use was (9.5%) (most of them were male). Other important aspects of drug use (e.g., source of acquiring drug) among the target population were reported. A significant association between drug use and some important factors was found. Conclusion: High prevalence of drug use was shown among the students and some factors appear to play a crucial role in drug use initiation, which necessitates preventive measures.


  • Open Access

    A A COMPARATIVE STUDY OF QUALITY CONTROL TESTING ON CANDESARTAN CILEXETIL CONVENTIONAL TABLETS IN IRAQ

    by Karrar Talib Khudhair Albo Hamrah, Abulfadhel Jaber Neamah Al-Shaibani, Sarmad Sabah Al-Edresi, Karrar Mohammed Hasan Al-Gburi

    Objective: The present study was performed to compare the quality of conventional tablets loaded with candesartan cilexetil. The selected candesartan cilexetil tablets were commercialized in the Iraq market and produced by different companies. Methods: Different batches of candesartan cilexetil oral tablets (the concentration of candesartan was 8 mg) were subjected to quality control tests. Tests included weight variation, friability, hardness, drug content, disintegration time and in vitro release study. The protocols of these tests were performed according to USP pharmacopeia. Results: The results, in this study, revealed that all the used batches of candesartan cilexetil oral tablets complied with the specification of USP pharmacopeia for weight uniformity, friability value (% loss) was2, which was within the required limits (i.e. 4-8 Kg/cm2). Disintegration time wasin vitro release study indicated that the release of all marketed tablets exceeds 80 % within 15 min. Conclusion: All the studied tablets, loaded with candesartan cilexetil, were produced within the standard criteria of tablet production. The quality control analysis of the selected tablets, in this study, revealed satisfactory pharmaceutical properties (including safety and effectiveness) that comply within the limits of USP pharmacopeia.


  • Open Access

    DESIGN AND CHARACTERIZATION OF CANDESARTAN CILEXETIL ORAL NANOEMULSION CONTAINING GARLIC OIL

    by Abulfadhel Jaber Neamah Al-Shaibania, Karrar Mohammed Hasan Al-Gburib, Karrar Talib Khudhair Albo Hamraha, Ali Mohammed Abd Alridhab

    Objective: This study was designed to prepare and characterize oil in water (o/w) nanoemulsion of candesartan cilexetil for oral administration. Preparation of candesartan cilexetil as nanoemulsion could increase its water solubility and thus could enhance its bioavailability. Methods: Aqueous titration method was used to construct the pseudo-ternary phase diagrams of nanoemulsion (NE) consisting of oil, various weight ratios of surfactant and co-surfactant (S mix), and deionized water. Different characterization techniques were conducted on the prepared nanoemulsions to obtain the optimized formula. Results: Characterizations of formula NE-4 (consists of 0.16% of candesartan cilexetil, 10% of garlic oil, 35 % of S mix (3:1) and 54.84% of deionized water) revealed the following characteristics: droplet size range (95-139 nm), polydispersity index (0.14), zeta potential value (-41.06 mV) and pH value (6.71), which are suitable for oral administration. Candesartan cilexetil in vitro release from this formula was significantly high (P<0.05) and scanning probe microscopy (SPM) study confirmed that the optimized formula (NE-4) was in nano-scale. Conclusion: Nanoemulsion formula 4 (NE-4) of candesartan cilexetil is the optimized formula and it could be a promising formula for improving the water solubility of candesartan cilaxetil.